

CITATION REPORT

List of articles citing

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study

DOI: 10.1038/ijo.2013.120

International Journal of Obesity, 2013, 37, 1443-51.

Source: <https://exaly.com/paper-pdf/55414230/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
454	A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet. 2010 , 18, 2301-10		22
453	The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. 2014 , 124, 4473-88		429
452	Endogenous Glucagon-Like Peptide-1 as a Potential Mediator of the Resolution of Diabetic Kidney Disease Following Roux en Y Gastric Bypass: Evidence and Perspectives. 2014 , 2014, 1-11		1
451	American association of clinical endocrinologists and american college of endocrinology consensus conference on obesity: building an evidence base for comprehensive action. 2014 , 20, 956-76		28
450	Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 809-22	4	20
449	Dynamic Models of Behavior for Just-in-Time Adaptive Interventions. 2014 , 13, 13-17		93
448	Obesity in primary care: prevention, management and the paradox. 2014 , 12, 149		7
447	Cosa c'è all'orizzonte della farmacologia dell'obesità? <i>L'Endocrinologo</i> , 2014 , 15, 207-212	0	
446	GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. 2014 , 34, 1174-86		59
445	Early therapy for type 2 diabetes in China. 2014 , 2, 992-1002		42
444	New molecular targets in the pathophysiology of obesity and available treatment options under investigation. 2014 , 4, 209-19		3
443	Impact of weight cycling on risk of morbidity and mortality. 2014 , 15, 870-81		67
442	Effects of exenatide in a morbidly obese patient with type 2 diabetes. 2014 , 5, 323-32		4
441	Pharmacotherapy for obesity: novel agents and paradigms. <i>Therapeutic Advances in Chronic Disease</i> , 2014 , 5, 135-48	4.9	68
440	Long-term drug treatment for obesity: a systematic and clinical review. 2014 , 311, 74-86		535
439	Tolerability and safety of the new anti-obesity medications. 2014 , 37, 693-702		59
438	Therapies for inter-relating diabetes and obesity - GLP-1 and obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 2487-500	4	29

437	Liraglutide in the treatment of obesity. 2014 , 14, 1215-24	14
436	Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies. 2015 , 23 Suppl 2, S1-S26	40
435	Current and emerging medications for overweight or obesity in people with comorbidities. 2015 , 17, 1021-32	48
434	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan 2015. 2015 , 21, 1-87	390
433	Food preferences and underlying mechanisms after bariatric surgery. 2015 , 74, 419-25	58
432	Studio randomizzato, controllato sugli effetti della Liraglutide alla dose di 3 mg nel trattamento dell'obesità. <i>L'Endocrinologo</i> , 2015 , 16, 183-183	0
431	Hochdosiertes GLP-1-Analogon zur Gewichtskontrolle erfolgreich. 2015 , 9, 27-28	0
430	Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension. 2015 , 15, 63	18
429	Liraglutide: A New Option for the Treatment of Obesity. 2015 , 35, 926-34	72
428	Obesity medications: what does the future look like?. 2015 , 22, 360-6	14
427	A randomized clinical trial of a weight loss maintenance intervention in a primary care population. 2015 , 23, 2015-21	14
426	Anti-obesity drugs. 2015 , 26, 536-43	21
425	New and emerging drugs for the treatment of obesity. 2015 , 58, 452	
424	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. 2015 , 21, 1403-14	20
423	Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain. 2015 , 53, 19-22	2
422	Recent Advances for Anti-Obesity Agents. <i>Journal of Korean Diabetes</i> , 2015 , 16, 260	0.1
421	Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide. 2015 , 6, 807-27	48
420	Obesity: Lifestyle management, bariatric surgery, drugs, and the therapeutic exploitation of gut hormones. 2015 , 127, 494-502	14

419	Liraglutide: a review of its use in the management of obesity. 2015 , 75, 899-910	23
418	Liraglutide: an injectable option for the management of obesity. 2015 , 49, 938-44	14
417	Incretin-based therapies: where will we be 50 years from now?. 2015 , 58, 1745-50	35
416	Liraglutide and obesity: a review of the data so far. 2015 , 9, 1867-75	63
415	GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. 2015 , 23, 1119-29	48
414	Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes. 2015 , 39 Suppl 5, S134-41	12
413	European Guidelines for Obesity Management in Adults. 2015 , 8, 402-24	509
412	2014 EASO Position Statement on the Use of Anti-Obesity Drugs. 2015 , 8, 166-74	33
411	New medications for treatment of obesity: metabolic and cardiovascular effects. 2015 , 31, 142-52	41
410	Rapid and body weight-independent improvement of endothelial and high-density lipoprotein function after Roux-en-Y gastric bypass: role of glucagon-like peptide-1. 2015 , 131, 871-81	82
409	Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling. 2015 , 145, 672-80	65
408	NIH working group report: Innovative research to improve maintenance of weight loss. 2015 , 23, 7-15	304
407	GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. 2015 , 64, 2513-25	171
406	Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice. 2015 , 293, 96-106	71
405	A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. 2015 , 373, 11-22	950
404	Glucagon-like peptide 1 deficiency in type 1 diabetes?. 2015 , 52, 191-2	
403	Liraglutide for Type 2 diabetes and obesity: a 2015 update. 2015 , 13, 753-67	41
402	Biologic Responses to Weight Loss and Weight Regain: Report From an American Diabetes Association Research Symposium. 2015 , 64, 2299-309	33

401	Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer. 2015 , 14, 171-80		23
400	Pancreatic Amylase and Lipase Plasma Concentrations Are Unaffected by Increments in Endogenous GLP-1 Levels Following Liquid Meal Tests. 2015 , 38, e71-2		10
399	Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss. <i>International Journal of Obesity</i> , 2015 , 39, 834-41	5.5	51
398	ANTI-OBESITY PHARMACOTHERAPY AND THE POTENTIAL FOR PREVENTING PROGRESSION FROM PREDIABETES TO TYPE 2 DIABETES. 2015 , 21, 634-44		6
397	Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. <i>International Journal of Obesity</i> , 2015 , 39, 849-57	5.5	5
396	Next generation of weight management medications: implications for diabetes and CVD risk. 2015 , 17, 35		13
395	Physiological adaptations to weight loss and factors favouring weight regain. <i>International Journal of Obesity</i> , 2015 , 39, 1188-96	5.5	191
394	The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. 2015 , 15, 14		30
393	The New Era of Drug Therapy for Obesity: The Evidence and the Expectations. 2015 , 75, 935-45		37
392	Correction to: Therapies for inter-relating diabetes and obesity [GLP-1 and obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 147	4	
391	Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial. 2015 , 35, 675-84		8
390	Liraglutide in obesity: a guide to its use in the EU. 2015 , 31, 334-340		
389	The 2013 American Heart Association/American College of Cardiology/The Obesity Society Guideline for the Management of Overweight and Obesity in Adults: What Is New About Diet, Drugs, and Surgery for Obesity?. 2015 , 132, 1586-91		17
388	Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies. 2015 , 127, 480-93		5
387	Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. 2015 , 38, 1567-82		133
386	Pharmacotherapy for the management of obesity. 2015 , 64, 1376-85		72
385	Pharmacotherapy for the treatment of obesity. 2015 , 418 Pt 2, 173-83		23
384	Horizons in the Pharmacotherapy of Obesity. 2015 , 4, 451-9		12

383	Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. 2015 , 55, 497-504	85
382	Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus. 2015 , 17, 231-44	9
381	Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials. 2015 , 7, 329-39	29
380	EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HISPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS. 2016 , 22, 1277-1287 ¹¹	11
379	Pancreas Volume and Fat Deposition in Diabetes and Normal Physiology: Consideration of the Interplay Between Endocrine and Exocrine Pancreas. 2016 , 13, 132-147	26
378	The Use of Rat and Mouse Models in Bariatric Surgery Experiments. 2016 , 3, 25	23
377	Arznei boostert Gewichtsreduktion. 2016 , 10, 56-56	1
376	Defining the role of metabolic physician. 2016 , 171-181	
375	Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity. 2016 , 7, 572-598	31
374	The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond. 2016 , 17, 553-72	21
373	Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. 2016 , 18, 558-70	92
372	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. 2016 , 22 Suppl 3, 1-203	557
371	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. 2016 , 22, 84-113	333
370	Management of Obesity. 2016 , 34, 4295-4305	35
369	Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease. 2016 , 1646, 354-365	24
368	Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity. <i>Current Atherosclerosis Reports</i> , 2016 , 18, 36	6 9
367	¿Existe un espacio para los análogos de la incretina como terapia para el sobrepeso, la obesidad y la prevención de la enfermedad cardio-metabólica?. 2016 , 23, 200-209	1
366	Proactive and Progressive Approaches in Managing Obesity. 2016 , 128 Suppl 1, 21-30	5

365	Timing the discussion of antiobesity medications during obesity treatment. 2016 , 24, 2027-8	3
364	Can we win the war on obesity with pharmacotherapy?. 2016 , 9, 1289-1297	8
363	An update on naltrexone/bupropion extended-release in the treatment of obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2235-2242	4 6
362	Pharmacotherapy for Obesity. 2016 , 45, 521-38	26
361	Drugs to treat obesity: do they work?. 2016 , 92, 401-6	8
360	Type 2 Diabetes Treatment in the Patient with Obesity. 2016 , 45, 553-64	2
359	Review of pharmacotherapy options for the management of obesity. 2016 , 28, 107-15	2
358	Weight maintenance: challenges, tools and strategies for primary care physicians. 2016 , 17, 81-93	49
357	Investigational glucagon-like peptide-1 agonists for the treatment of obesity. 2016 , 25, 1167-79	15
356	Cardiovascular Effects of the New Weight Loss Agents. 2016 , 68, 849-59	16
355	Liraglutide, GLP-1 receptor agonist, for chronic weight loss. 2016 , 11, 373-378	3
354	Liraglutide ameliorates palmitate-induced endothelial dysfunction through activating AMPK and reversing leptin resistance. 2016 , 478, 46-52	24
353	Role of glucagon-like peptide 1 receptor agonists in management of obesity. 2016 , 73, 1493-507	30
352	Use of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology of dual GIPR/GLP-1R agonists. 2016 , 473, 2881-91	33
351	Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. 2016 , 18, 1176-1190	132
350	Intragastric Balloon for Management of Severe Obesity: a Systematic Review. 2016 , 26, 2248-2254	71
349	Physiology, pathophysiology and therapeutic implications of enteroendocrine control of food intake. 2016 , 11, 475-499	13
348	Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials. 2016 , 18, 430-5	15

347	Role of Bupropion Plus Naltrexone for the Management of Obesity. 2016 , 32, 125-132		1
346	Optimizing management of glycaemia. 2016 , 30, 397-411		5
345	Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents. 2016 , 30, 357-71		11
344	Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. <i>International Journal of Obesity</i> , 2016 , 40, 1310-5.5		150
343	A Comparison of New Pharmacological Agents for the Treatment of Obesity. 2016 , 50, 376-88		16
342	GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. 2016 , 59, 954-65		121
341	Management of obesity. 2016 , 387, 1947-56		461
340	Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. 2016 , 12, 129-38		16
339	The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. <i>Therapeutic Advances in Chronic Disease</i> , 2016 , 7, 92-107	4-9	27
338	THERAPY OF ENDOCRINE DISEASE: Testosterone supplementation and body composition: results from a meta-analysis study. 2016 , 174, R99-116		144
337	Gastrointestinal traits: individualizing therapy for obesity with drugs and devices. 2016 , 83, 48-56		21
336	Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience. 2015 , 10, 164-74		7
335	Current Perspectives on Long-term Obesity Pharmacotherapy. 2016 , 40, 184-91		15
334	The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. 2016 , 77, 28-37		160
333	New Targets for Drug Treatment of Obesity. 2017 , 57, 585-605		28
332	Liraglutide for weight management: a critical review of the evidence. 2017 , 3, 3-14		110
331	Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. 2017 , 19, 906-908		59
330	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. 2017 , 389, 1399-1409		324

329	Exenatide improves liver mitochondrial dysfunction and insulin resistance by reducing oxidative stress in high fat diet-induced obese mice. 2017 , 486, 116-123	14
328	Glucagon-like peptide-1 agonists for weight loss in people with obesity. 2017 , 5, 29-43	
327	A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease. 2017 , 117, 238-248	46
326	Bariatric surgery - time to replace with GLP-1?. 2017 , 52, 635-640	15
325	Vascular risk in obesity: Facts, misconceptions and the unknown. 2017 , 14, 2-13	19
324	Type 2 diabetes. 2017 , 389, 2239-2251	935
323	Practical Use of Pharmacotherapy for Obesity. 2017 , 152, 1765-1779	44
322	Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. 2017 , 102, 709-757	485
321	Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. 2017 , 5, CD012204	23
320	Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. 2017 , 40, 839-848	33
319	Therapy: Liraglutide - preventing or postponing T2DM diagnosis?. 2017 , 13, 320-322	1
318	Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists. 2017 , 60, 4293-4303	69
317	LIMITED CARBOHYDRATE REFEEDING INSTRUCTION FOR LONG-TERM WEIGHT MAINTENANCE FOLLOWING A KETOGENIC, VERY-LOW-CALORIE MEAL PLAN. 2017 , 23, 649-656	8
316	Epidemiology of Obesity and Pharmacologic Treatment Options. 2017 , 32, 441-462	15
315	Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice. 2017 , 17, 34	28
314	Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. 2017 , 19, 1529-1536	27
313	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. 2017 , 23, 207-238	302
312	Pharmacotherapy for Weight Management in the VHA. 2017 , 32, 70-73	12

311	Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years. 2017 , 181, 146-153.e3	58
310	Past, present and future of pharmacotherapy for obesity. 2017 , 29, 256-264	2
309	Bariatric Surgery Resistance: Using Preoperative Lifestyle Medicine and/or Pharmacology for Metabolic Responsiveness. 2017 , 27, 3281-3291	13
308	Obesity management among patients with type 2 diabetes and prediabetes: a focus on lifestyle modifications and evidence of antiobesity medications. 2017 , 12, 303-313	3
307	A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. 2017 , 9,	36
306	Current and emerging pharmacotherapies for obesity in Australia. 2017 , 11, 501-521	7
305	Approaches to obesity management. 2017 , 47, 734-739	12
304	Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease. 2017 , 29, 185-200	
303	Obesity. 2017 , 477-498	1
302	Obesity and Weight Loss in Idiopathic Intracranial Hypertension: A Narrative Review. 2017 , 37, 197-205	42
301	Potential Hormone Mechanisms of Bariatric Surgery. 2017 , 6, 253-265	79
300	Weight management in adults. 2017 , 139-259	
299	Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m ² : A Post-hoc Analysis. 2017 , 10, 531-544	19
298	Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development. 2017 , 31, 399-421	2
297	Usò della liraglutide nel trattamento dell'obesità. <i>L'Endocrinologo</i> , 2017 , 18, 42-43	0
296	Lorcaserin plus lifestyle modification for weight loss maintenance: Rationale and design for a randomized controlled trial. 2017 , 59, 105-112	13
295	The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg. 2017 , 9, 44	33
294	Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects. 2017 , 33, 225-229	17

293	Bench to bedside in appetite research: Lost in translation?. 2017 , 76, 163-173	4
292	Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease. 2017 , 29, 185-200	6
291	Effects of lorcaserin on pre-existing valvulopathy: A pooled analysis of phase 3 trials. 2017 , 25, 39-44	12
290	Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity. 2017 , 18, 86-98	36
289	Adipositas und Prdiabetes. 2017 , 13, 482-486	
288	Weight loss medications in Canada - a new frontier or a repeat of past mistakes?. 2017 , 10, 413-417	7
287	The Management of Obesity: An Overview. 2017 , 47-57	
286	? Liraglutide for weight management. 2017 , 55, 78-81	1
285	Diet and Weight Management. 2018 , 71-82	
284	Glucagon-Like Peptide 1 and Human Obesity. 2018 , 17-36	1
283	A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States. 2018 , 21, 835-844	4
282	Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK. 2018 , 8, 211-225	6
281	Medically Supervised Weight Loss Programs. 2018 , 211-223	
280	Safety and tolerability of new-generation anti-obesity medications: a narrative review. 2018 , 130, 173-182	64
279	Updates on obesity pharmacotherapy. 2018 , 1411, 106-119	38
278	The safety of pharmacologic treatment for pediatric obesity. 2018 , 17, 379-385	23
277	New Therapies in Obesity. 2018 , 271-279	0
276	A Randomized Trial of Lorcaserin and Lifestyle Counseling for Maintaining Weight Loss Achieved with a Low-Calorie Diet. 2018 , 26, 299-309	16

275	Obesity: Pathophysiology and Management. 2018 , 71, 69-84		192
274	Glucagon-like peptide 1 in health and disease. 2018 , 14, 390-403		187
273	Pharmacotherapeutic strategies for treating hypertension in patients with obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 643-651	4	8
272	The Science of Obesity Management: An Endocrine Society Scientific Statement. 2018 , 39, 79-132		304
271	Pharmacotherapy for Patients with Obesity. 2018 , 64, 118-129		29
270	Current pharmacotherapy for obesity. 2018 , 14, 12-24		192
269	Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials. 2018 , 20, 734-739		42
268	Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option. 2018 , 66, 7-10		36
267	Progress and challenges in anti-obesity pharmacotherapy. 2018 , 6, 237-248		118
266	Addressing Obesity in Aging Patients. 2018 , 102, 65-85		65
265	Protein sparing therapies in acute illness and obesity: a review of George Blackburn's contributions to nutrition science. 2018 , 79, 83-96		10
264	Obesity Pharmacotherapy. 2018 , 102, 135-148		68
263	Incretin System: New Pharmacological Target in Obese Women with Polycystic Ovary Syndrome. 2018 ,		0
262	Gold nanoparticles as cell regulators: beneficial effects of gold nanoparticles on the metabolic profile of mice with pre-existing obesity. 2018 , 16, 88		13
261	Reprint of: Healthy Weight and Obesity Prevention: JACC Health Promotion Series. 2018 , 72, 3027-3052		20
260	VLCD for weight loss and remission of type 2 diabetes?. 2018 , 392, 1306-1307		3
259	The Role of Weight Management in the Treatment of Adult Obstructive Sleep Apnea. An Official American Thoracic Society Clinical Practice Guideline. 2018 , 198, e70-e87		78
258	Healthy Weight and Obesity Prevention: JACC Health Promotion Series. 2018 , 72, 1506-1531		172

257	A randomized controlled trial of lorcaserin and lifestyle counselling for weight loss maintenance: changes in emotion- and stress-related eating, food cravings and appetite. 2018 , 8, 383-390		9
256	Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. 2018 , 320, 1172-1191		173
255	Addressing Obesity in Clinical Gynecology Practice. 2018 , 61, 10-26		3
254	Why Weight? An Analytic Review of Obesity Management, Diabetes Prevention, and Cardiovascular Risk Reduction. <i>Current Atherosclerosis Reports</i> , 2018 , 20, 39	6	15
253	Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. 2018 , 28, 23-32.e3		49
252	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. 2018 , 24, 91-120		321
251	Centrally Acting Agents for Obesity: Past, Present, and Future. 2018 , 78, 1113-1132		52
250	Efficacy of High-Dose Liraglutide as an Adjunct for Weight Loss in Patients with Prior Bariatric Surgery. 2018 , 28, 3553-3558		32
249	Gold nanoparticles improve metabolic profile of mice fed a high-fat diet. 2018 , 16, 11		21
248	Weight Loss Strategies for Treatment of Obesity: Lifestyle Management and Pharmacotherapy. 2018 , 61, 246-252		38
247	Treatment: New Drugs. 2019 , 464-472		
246	A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials. 2019 , 21, 120-128		84
245	Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study. 2019 , 73, e13399		24
244	Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies. 2019 , 21, 2459-2464		14
243	Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea. 2019 , 40, 63-71		4
242	Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities. 2019 , 79, 1187-1197		8
241	Response to "Liraglutide Effectiveness: Is There a Real-World Clinical Benefit?". 2019 , 27, 1728		
240	Impact of anti-obesity medication initiation and duration on weight loss in a comprehensive weight loss programme. 2019 , 5, 468-478		1

239	Safety and Efficacy of Weight-Loss Pharmacotherapy in Persons Living with HIV: A Review of the Literature and Potential Drug-Drug Interactions with Antiretroviral Therapy. 2019 , 39, 1204-1215	4
238	Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study. 2019 , 2, e00082	4
237	Farmacoterapia dell'obesità <i>L Endocrinologo</i> , 2019 , 20, 374-376	0
236	Cardiovascular risk and obesity. 2019 , 11, 74	106
235	CD1 is involved in diet-induced hypothalamic inflammation in obesity. 2019 , 78, 78-90	3
234	Incremental cost-effectiveness of evidence-based non-surgical weight loss strategies. 2019 , 9, e12294	13
233	Pharmaceutical approaches to weight management: behavioural mechanisms of action. 2019 , 12, 26-32	1
232	Combined effects of leaf and grape stalk extract in high-fat-diet-induced obesity in mice. 2019 , 28, 1207-1215	7
231	Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis. 2019 , 70, 1443-1456	8
230	Changes in gut hormones, glycaemic response and symptoms after oesophagectomy. 2019 , 106, 735-746	9
229	Quantifying Appetite and Satiety. 2019 , 121-140	
228	Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. 2019 , 20, 816-828	54
227	Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists. 2019 , 42, 957-971	11
226	Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. 2019 , 39, 941-949	31
225	The Discovery and Development of Liraglutide and Semaglutide. <i>Frontiers in Endocrinology</i> , 2019 , 10, 155	5-7 181
224	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. 2019 , 25, 69-100	191
223	Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients. 2019 , 21, 1498-1501	35
222	The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis. 2019 , 19, 2591-2599	7

221	Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet. 2019 , 9, e031431		3
220	Evolution of Endoscopic Bariatric Devices: From Development to Practice. 2019 , 114, 679-683		3
219	Current Treatments on Obesity. 2019 , 19, 171		2
218	GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy. 2019 , 18, 164		10
217	Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction. 2019 , 283, 28-34		7
216	Neuropeptide receptors as potential pharmacological targets for obesity. 2019 , 196, 59-78		7
215	Pharmacotherapy for Weight Management. 2019 , 395-411		1
214	Mechanisms of weight regain after weight loss - the role of adipose tissue. 2019 , 15, 274-287		50
213	Medications Indicated for Chronic Weight Management. 2019 , 401-424		
212	Pharmacologic Agents Chapter for Abdominal Obesity. 2019 , 51-66		1
211	Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. 2019 , 14, e12495		22
210	Pharmacotherapy of obesity: Available medications and drugs under investigation. 2019 , 92, 170-192		98
209	One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. 2019 , 139, 26-36		19
208	Obesity and Therapeutic Approaches to Weight Loss. 2019 , 71-85		
207	Choosing a Medication. 2019 , 105-119		
206	Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial. <i>International Journal of Obesity</i> , 2020 , 44, 353-361	5.5	12
205	Incretins in obesity and diabetes. 2020 , 1461, 104-126		32
204	An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 275-285	4	16

203	Anorectic state of obesity medications in the United States. Are leaner times ahead?. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 167-172	4	2
202	Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. 2020 , 13, 53-64		39
201	Reprint of: Recent Updates on Obesity Treatments: Available Drugs and Future Directions. 2020 , 447, 191-215		6
200	The risk of cardiovascular complications with current obesity drugs. 2020 , 19, 1095-1104		6
199	Obesity in adults: a clinical practice guideline. 2020 , 192, E875-E891		192
198	Long-Term Changes in Weight in Patients With Severe and Complicated Obesity After Completion of a Milk-Based Meal Replacement Programme. 2020 , 7, 551068		0
197	Weight loss: Lifestyle interventions and pharmacotherapy. 2020 , 219-234		
196	Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection. 2020 , 9, 391-401		3
195	A narrative review of current trends in liraglutide: insights into the unmet needs in management of type 2 diabetes and obesity. 2020 , 19, 1863-1872		3
194	A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?. 2020 , 22, 2227-2240		8
193	Early Post-operative Weight Change After Roux-en-Y Gastric Bypass Predicts Weight Loss at 12-Month Follow-up. 2020 , 30, 5020-5025		2
192	Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare [®] patient support program. 2020 , 6, 382-389		2
191	Recent Updates on Obesity Treatments: Available Drugs and Future Directions. 2020 , 437, 215-239		23
190	Very-Low-Calorie Ketogenic Diets With Whey, Vegetable, or Animal Protein in Patients With Obesity: A Randomized Pilot Study. 2020 , 105,		34
189	Medications Available for Weight Reduction in Elective Total Joint Arthroplasty. 2020 , 8, e0123		0
188	The pivotal relation between glucagon-like peptides, NFB and inflammatory bowel disease. 2020 , 47, 1641-1648		2
187	A Role for GLP-1 in Treating Hyperphagia and Obesity. 2020 , 161,		25
186	Brain insulin resistance: role in neurodegenerative disease and potential for targeting. 2020 , 29, 333-348		44

185	A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. 2020 , 382, 2117-2128	120
184	Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center. 2020 , 43, 1779-1785	6
183	Pharmacological therapies to address obesity in type 1 diabetes. 2020 , 27, 194-206	3
182	Legend of Weight Loss: a Crosstalk Between the Bariatric Surgery and the Brain. 2020 , 30, 1988-2002	16
181	Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX). 2020 , 124, 9-12	4
180	The Societal Value of Broader Access to Antiobesity Medications. 2020 , 28, 429-436	4
179	The role of appetite-related hormones, adaptive thermogenesis, perceived hunger and stress in long-term weight-loss maintenance: a mixed-methods study. 2020 , 74, 622-632	19
178	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM -. 2020 , 26, 107-139	206
177	PyRod Enables Rational Homology Model-based Virtual Screening Against MCHR1. 2020 , 39, e2000020	1
176	Drug Therapy in Obesity: A Review of Current and Emerging Treatments. 2020 , 11, 1199-1216	56
175	Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers. 2021 , 133, 310-319	4
174	Reversal of Long-Term Weight Regain After Roux-en-Y Gastric Bypass Using Liraglutide or Surgical Revision. A Prospective Study. 2021 , 31, 93-100	11
173	Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss. 2021 , 93, 1316-1324.e1	7
172	Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging. 2021 , 18, 291-304	33
171	Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect. 2021 , 12, 261-274	13
170	Herbal nanotherapy: A new paradigm over conventional obesity treatment. 2021 , 61, 102291	6
169	Clinical Impact of Weight-Loss Pharmacotherapy in Patients with Atherosclerotic Cardiovascular Disease. 2021 , 21, 271-281	3
168	Brief formula low-energy-diet for relapse management during weight loss maintenance in the Diabetes Remission Clinical Trial (DiRECT). 2021 , 34, 472-479	4

167	Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia. 2021 , 100, e23780	4
166	Pharmacologie de l'obésité vers de nouvelles options. 2021 , 663-672	
165	Obesity: Medical and Surgical Treatment. 2021 , 131-175	
164	Liraglutide for overweight and obesity. 2021 , 38, 7	2
163	Simulating the Fiscal Impact of Anti-Obesity Medications as an Obesity Reduction Strategy. 2021 , 58, 46958021990516	1
162	Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. 2021 , 113, 314-323	9
161	Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. 2021 , 39, 208-221	21
160	Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists. 2021 , 212, 113118	5
159	Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?. 2021 , 13,	7
158	The SEEN comprehensive clinical survey of adult obesity: Executive summary. 2021 , 68, 130-136	1
157	INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES". 2021 , 18, 5-99	20
156	The SEEN comprehensive clinical survey of adult obesity: Executive summary. 2021 , 68, 130-136	4
155	Abnehmen mit Arzneimitteln? Pharmakotherapie von Übergewicht und Adipositas. 2021 , 46, 41-55	
154	An update on pharmacotherapeutic strategies for obesity. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1305-1318	4 3
153	The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial. 2021 , 23, 1262-1271	7
152	Anorectic interaction and safety of 5-hydroxytryptophan/carbidopa plus phentermine or diethylpropion in rat. 2021 , 32, 368-381	
151	Clinical Impact of Liraglutide as a Treatment of Obesity. 2021 , 13, 53-60	4
150	Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. 2021 , 325, 1414-1425	102

149	Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?. 2021 , 81, 881-893		2
148	Approach to Obesity in the Elderly. 2021 ,		0
147	Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. <i>Advances in Therapy</i> , 2021 , 38, 2821-2839	4.1	10
146	Cardiovascular safety of long-term anti-obesity drugs in subjects with overweight or obesity: a systematic review and meta-analysis. 2021 , 77, 1611-1621		2
145	In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine. 2021 , 1		0
144	Liraglutide pharmacokinetics and exposure-response in adolescents with obesity. 2021 , 16, e12799		1
143	Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders. 2021 ,		11
142	Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. 2021 , 384, 1719-1730		43
141	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). 2021 , 6-61		2
140	Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials. 2021 , 36, 647-660		4
139	Glucagon-Like Peptide-1 (GLP-1) Receptor Agonism and Exercise: An Effective Strategy to Maintain Diet-Induced Weight Loss. 2021 , 42, 2628-2629		
138	Obesity and GLP-1. 2021 , 46, 168-176		4
137	Role of Glucose-Lowering Medications in Erectile Dysfunction. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
136	A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer's Perspective. 2021 , 14, 3147-3160		
135	Pharmacotherapy in Childhood Obesity. 2021 ,		0
134	Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists. 2021 , 30, 1016-1027		1
133	Efficacy of Dietary and Supplementation Interventions for Individuals with Type 2 Diabetes. 2021 , 13,		2
132	Patient initiation and maintenance of GLP-1 RAs for treatment of obesity. 2021 , 14, 1193-1204		5

131	Diets and drugs for weight loss and health in obesity - An update. 2021 , 140, 111789		11
130	The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. 2021 ,		10
129	Effects of weight loss medications on mortality and cardiovascular events: A systematic review of randomized controlled trials in adults with overweight and obesity. 2021 , 31, 2587-2595		0
128	[Medical therapy of obesity in France in 2021]. 2021 , 42, 519-522		
127	Obesity Management in Cardiometabolic Disease: State of the Art. <i>Current Atherosclerosis Reports</i> , 2021 , 23, 59	6	3
126	Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes. 2021 , 30, 233-247		1
125	Obesity-An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances. 2021 , 11,		1
124	Anti-diabetic drugs and weight loss in patients with type 2 diabetes. 2021 , 171, 105782		9
123	Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study. 2021 , 70, 2903-2916		14
122	Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. 2021 ,		22
121	Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. 2021 , 9, 595-605		10
120	Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY Combination Therapy in Diet-Induced Obese Rats. <i>Frontiers in Endocrinology</i> , 2020 , 11, 598843	5.7	4
119	Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. <i>International Journal of Obesity</i> , 2021 , 45, 923-933	5.5	9
118	Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?. 2021 , 10, 14-30		31
117	Type 2 Diabetes Mellitus. 2021 ,		
116	Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention. <i>International Journal of Obesity</i> , 2021 , 45, 776-786	5.5	7
115	Obesity therapy. <i>Clinical Nutrition ESPEN</i> , 2020 , 38, 9-18	1.3	5
114	[Pharmacological treatment of obesity for Primary Care physicians]. 2019 , 45, 559-565		1

113	GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report. 2020 , 1, 100006	8
112	Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial. 2020 , 10, e034137	1
111	Treatment of Obesity in Mitigating Metabolic Risk. 2020 , 126, 1646-1665	18
110	Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. 2020 , 105,	38
109	Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology. 2019 , 36, 67-77	3
108	Gglucagon-like peptide-1 analogue liraglutide (Saxenda [®]): mechanism of action, efficacy for the treatment of obesity. 2018 , 15, 3-11	5
107	. 2020 , 192, E1757-E1775	1
106	Liraglutide for the Treatment of Obesity: Analyzing Published Reviews. 2019 , 25, 1783-1790	4
105	Current Options for the Pharmacotherapy of Obesity. 2019 , 25, 2019-2032	2
104	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. 2019 , 17, 515-537	12
103	Multidimensional Cognitive Behavioral Therapy for Obesity Applied by Psychologists Using a Digital Platform: Open-Label Randomized Controlled Trial. 2020 , 8, e14817	7
102	New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists. 2020 , 45, 127-137	12
101	Guidelines on treatment of patients with arterial hypertension comorbid with metabolic disorders and diabetes mellitus type 2. 2020 , 17, 7-45	13
100	Text messaging and financial incentives to encourage weight loss in men with obesity: the Game of Stones feasibility RCT. 2020 , 8, 1-224	2
99	Comprehensive Review of Current and Upcoming Anti-Obesity Drugs. 2020 , 44, 802-818	17
98	Treating morbid obesity in cirrhosis: A quest of holy grail. 2015 , 7, 2819-28	14
97	Current Long-Term Pharmacotherapies for the Management of Obesity. 2020 , 29, 99-109	3
96	GLP-1 physiology informs the pharmacotherapy of obesity. 2021 , 57, 101351	9

95	Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. 2021 ,	4
94	The Doctor's Tool Kit: Pharmacotherapy for the Patient with Obesity. 2015 , 91-109	
93	Individualizing Lifestyle Therapy for Patients with Obesity. 2016 , 22, 14-20	
92	Medications Indicated for Chronic Weight Management. 2017 , 1-24	
91	Liraglutid bei Adipositas. 2017 , 39,	
90	Obesity and type 2 diabetes: can we find a compromised treatment solution?. 2017 , 20, 270-278	4
89	Recent Advances in Anti-Obesity Agents. 2018 , 93, 501-508	7
88	Short-term monotherapy with Liraglutide for weight management: A case study. 2019 , 8, 1804-1806	1
87	Tratamento farmacológico da obesidade: passado, presente e futuro.. 2019 , 44, 261-268	0
86	Multidimensional Cognitive Behavioral Therapy for Obesity Applied by Psychologists Using a Digital Platform: Open-Label Randomized Controlled Trial (Preprint).	
85	Therapeutic Management of Obesity. 2021 , 323-339	1
84	MS-275, a class 1 histone deacetylase inhibitor augments glucagon-like peptide-1 receptor agonism to improve glycemic control and reduce obesity in diet-induced obese mice. 2020 , 9,	3
83	Obesity and Its Complications Pathogenesis. 2020 , 43-56	
82	Choosing Medications for Weight Loss in Type 2 Diabetes Mellitus. 2021 , 187-197	
81	Cardiovascular safety profile of currently available diabetic drugs. 2014 , 14, 616-32	27
80	Obesity Management: Clinical Review and Update of the Pharmacologic Treatment Options. 2016 , 33, 6-16	1
79	Diet and exercise in the management of PCOS: Starting from the basics. 2022 , 97-115	
78	Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. <i>International Journal of Obesity</i> , 2021 ,	5.5 3

77	Long-term weight loss maintenance with obesity pharmacotherapy: A retrospective cohort study.	0
76	Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis. <i>EClinicalMedicine</i> , 2021 , 42, 101213	11.3 5
75	Predictive Modeling for Decision Support in the Tasks of Selecting the Drug for Obesity Treatment. 2021 , 193, 371-381	
74	Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.. 2022 , 327, 138-150	29
73	Drugs for Treating Obesity. 2021 ,	3
72	New Horizons A New Paradigm for Treating to Target with Second-Generation Obesity Medications. 2021 ,	5
71	Pharmacological Treatment of Obesity. 2022 , 435-442	
70	Advances in Phenotyping Obesity and in Its Dietary and Pharmacological Treatment: A Narrative Review.. 2022 , 9, 804719	1
69	Integrating High-Dose GLP-1 Receptor Agonists Into the Care of People With or at Risk for Type 2 Diabetes. 2633559X2210862	
68	What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review.. 2022 ,	1
67	Implementation of Cardiometabolic Centers and Training Programs.. 2022 , 1	
66	Review article: Role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.. 2022 ,	1
65	Adjunctive Therapy, Including Pharmacotherapy. 2022 , 279-296	
64	Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors.. 2022 , 23,	1
63	The Behavioral Treatment of Obesity. 2022 , 249-261	
62	Effect of GLP-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: a meta-analysis of placebo-controlled randomized trials.. 2022 ,	1
61	A contemporary view on obesity treatment in adults. 2021 , 45-50	2
60	NSAID-Induced Enteropathy Affects Regulation of Hepatic Glucose Production by Decreasing GLP-1 Secretion.. 2021 , 14,	1

59	Semaglutide for the Treatment of Obesity.. 2021 ,			3
58	Adding liraglutide to diet and exercise to maintain weight loss - is it worth it?. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 1-5			4
57	Obesity: Current Treatment Options in Adults. 2020 , 342-361			
56	Exenatide for weight-loss maintenance in adolescents with severe obesity: A randomized, placebo-controlled trial.. 2022 ,			0
55	Clinical Evaluation, Lifestyle, and Pharmacological Management of Obesity. 2022 , 221-240			
54	Effectiveness, tolerability, and pattern of liraglutide treatment use for weight loss: a mixed-methods cohort study. <i>Journal of Advanced Pharmacy Education and Research</i> , 2022 , 12, 63-70			
53	Incidence of adhesions in patients using liraglutide before laparoscopic sleeve gastrectomy.. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022 ,		5.2	
52	Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review.. <i>Advances in Therapy</i> , 2022 , 39, 2452-2467		4.1	4
51	Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management. <i>Current Atherosclerosis Reports</i> ,		6	0
50	Efficacy of Liraglutide in Non-Diabetic Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine</i> , 2022 , 11, 2998		5.1	2
49	Fast-track rescue weight reduction therapy to achieve rapid technical operability for emergency bariatric surgery in patients with life-threatening inoperable severe obesity [A proof of concept study. <i>Clinical Nutrition ESPEN</i> , 2022 ,		1.3	0
48	Terapia farmacologica dell'obesità: attualità e prospettive future. <i>L Endocrinologo</i> ,		0	
47	GLP-1 analogues in clinical management of obesity. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2022 , 100360		1.7	0
46	The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy. <i>EClinicalMedicine</i> , 2022 , 49, 101436		11.3	1
45	Pharmacological Management of Obesity: A Century of Expert Opinions in Cecil Textbook of Medicine. <i>American Journal of Therapeutics</i> , Publish Ahead of Print,		1	
44	Medical Weight Management: A Multidisciplinary Approach.			
43	Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review. <i>Therapeutic Advances in Chronic Disease</i> , 2022 , 13, 204062232211080		4.9	1
42	Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery. <i>Eating and Weight Disorders</i> ,		3.6	2

41	Recent Advances in Anti-Obesity Drugs. <i>Journal of Korean Diabetes</i> , 2022 , 23, 113-127	0.1	1
40	Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Endocrinology</i> , 13,	5.7	0
39	A narrative review of anti-obesity medications for obese patients with osteoarthritis. <i>Expert Opinion on Pharmacotherapy</i> , 1-15	4	0
38	Pharmacologic treatment of obesity. 2022 , 65, 408-416		
37	Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis. 2022 , 2022, 1-14		2
36	Pharmacotherapy in obesity: the current state and the near future. 2022 , 65, 514-531		
35	WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan 2022 Update. 2022 ,		8
34	Adherence to and Dropout from Liraglutide Obesity Treatment in a Real-World Setting. 2022 ,		0
33	GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?. 2022 , 24, 867-884		0
32	Signaling pathways in obesity: mechanisms and therapeutic interventions. 2022 , 7,		4
31	Chinese herbal medicine is associated with higher body weight reduction than liraglutide among the obese population: A real-world comparative cohort study. 13,		0
30	Anti-obesity therapy for cardiovascular disease prevention: potential expected roles of glucagon-like peptide-1 receptor agonists. 2022 , 21,		0
29	Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials. 1-9		0
28	Semaglutide for the treatment of overweight and obesity: A review.		1
27	The effects and side effects of liraglutide as a treatment for obesity. 2022 , 4, 142-148		0
26	AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. 2022 , 163, 1198-1225		1
25	Parkinson disease and type 2 diabetes mellitus: interrelation of pathogenetic mechanisms and general therapeutic approaches. 2022 , 122, 12		0
24	New therapies for obesity.		2

- 23 Investigating the potential non-authorized use of two different formulations of liraglutide in Europe: A real-world drug utilization study. ○
- 22 A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management center. **2022**, 4, 100046 ○
- 21 A Study on Weight Loss Cause as per the Side Effect of Liraglutide. **2022**, 2022, 1-8 ○
- 20 Prehabilitation of overweight and obese patients with dysglycemia awaiting bariatric surgery: Predicting the success of obesity treatment. 13, 1096-1105 ○
- 19 GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. **2023**, 24, 1703 ○
- 18 New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. **2023**, 74, 125-139 ○
- 17 Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis. **2023**, 18, e0278685 ○
- 16 Combined lifestyle interventions. **2023**, 333-351 ○
- 15 Regulation of adipogenesis by exosomal milk miRNA. ○
- 14 Reliability of bioimpedance in the assessment of visceral fat in patients with obesity and metabolic syndrome treated with liraglutide for 6 months. ○
- 13 GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. 14, ○
- 12 Association of obesity and cardiovascular disease and progress in pharmacotherapy: what is next for obesity?. **2023**, 46, 14-25 ○
- 11 Pharmacological Support for the Treatment of Obesity Present and Future. **2023**, 11, 433 1
- 10 Hormonal Gut-Brain Signaling for the Treatment of Obesity. **2023**, 24, 3384 ○
- 9 Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. **2023**, 32, 25-45 ○
- 8 FALCON systematically interrogates free fatty acid biology and identifies a novel mediator of lipotoxicity. ○
- 7 Metabolically healthy obesity: Misleading phrase or healthy phenotype?. **2023**, 111, 5-20 ○
- 6 Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function. **2023**, 31, 977-989 ○

- 5 Obesity in Adults: Position Statement of Polish Association for the Study on Obesity, Polish Association of Endocrinology, Polish Association of Cardiometabolism, Polish Psychiatric Association, Section of Metabolic and Bariatric Surgery of the Association of Polish Surgeons, and the College of Family Physicians in Poland. **2023**, 15, 1641
- 4 GLP-1 analogues in the treatment of obesity and non-alcoholic fatty liver disease. **2023**, 77, 1-8
- 3 Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options. **2023**, 28, 3094
- 2 Weight loss to disrupt type 2 diabetes.
- 1 Medications for obesity management: Effectiveness and value. **2023**, 29, 569-575